Key Highlights
- Invion (ASX:IVX) received AUD 502,675 in net proceeds under the FY26 Research and Development tax incentive.
- The cash refund relates to eligible Australian research expenditure.
- The company is planning a Phase II skin cancer trial and an anogenital cancer trial.
- Two earlier financing arrangements were designed to cover up to approximately 85% of future clinical trial costs, according to Invion.
Invion (ASX:IVX) develops Photosoft photodynamic therapy and is evaluating its lead investigational cancer candidate, INV043. On 19 November 2026, the company announced receipt of a cash refund under Australia’s research and development tax incentive. The payment relates to eligible FY26 research and sits alongside financing arrangements announced in October.
FY26 payment and the source of funds
Invion reported receiving AUD 502,675 in net proceeds from the Australian Government’s research and development tax incentive. The cash refund relates to research activity undertaken in Australia. The November release described the payment as support for ongoing development work and identified the tax incentive as a component of the company’s funding strategy. Invion’s research work includes the Photosoft platform and studies of INV043 in several indications. The reported amount describes cash received under the FY26 incentive.
Invion’s September Quarterly Report showed AUD 512,000 in period-end cash and AUD 18,000 in net operating cash inflow. That report recorded AUD 545,000 in research tax incentives during the September period. It listed AUD 338,000 in research and development costs and AUD 189,000 in administration and corporate costs for September. The FY26 refund discussed in the 19 November notice was announced after that reporting period.
October arrangement for clinical invoices
Invion reported a multi-year co-funding agreement in October. It provides for contributions of half of eligible clinical research organisation invoices or milestone payments up to a cumulative AUD 25 million, with funding to be drawn in stages. Under the announced terms, consideration includes unlisted share Options subject to Shareholder approval for grant. Exercise depends on the provision of funding and a trial candidate reaching Phase III. Invion linked the funding arrangement to its current and future clinical work and said the staged use would be based on the scope of its programs.
Separate financing against expected offsets
The second arrangement is a secured Facility of up to AUD 7.5 million in aggregate for FY27 and FY28. Invion said it was structured against eligible expenditure, allowing it to fund clinical research invoices ahead of receiving associated tax offsets. The October disclosure identified a borrowing base linked to the refundable offset and described conditions for advances. The facility carries an annual Interest Rate of 16% and a drawdown fee of 1.5%. Invion’s estimate of coverage from the two agreements was up to approximately 85% of clinical trial costs.
The programs identified in the November release
The company named its planned Phase II skin cancer trial and a planned anogenital trial co-sponsored by the Peter MacCallum Cancer Centre among its clinical programs. Its earlier funding release described the skin cancer program as focusing on non-melanoma skin cancer. The company is developing INV043 using its Photosoft platform. The 19 November announcement covered funds received under the tax incentive and referred to the clinical programs it is preparing to advance.
The earlier quarterly report said recruitment had closed in the Phase I skin cancer study and that all patient treatments had been completed. Invion identified Phase II as its planned next step.
Invion’s update puts a received FY26 cash refund alongside previously announced facilities for future clinical spending. The company differentiated the received amount from funding expected to be accessed as trial invoices and milestones arise.






Please wait processing your request...